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The Gates Foundation is funding high-risk research into new ways to improve health in 
developing countries, but ensuring that the fruits of these studies reach the people who 
need them most may be the biggest challenge of all.Several years ago, Microsoft cofounder 
Bill Gates asked a simple question: 
Were enough of the world’s bright-
est minds in science and technol-
ogy directed at solving the daunt-
ing health problems of developing 
nations? Finding that the answer was 
no, the Bill & Melinda Gates Foun-
dation set out to engage the scien-
tific research community with a new 
funding initiative called the Grand 
Challenges in Global Health.
In 2003, an illustrious interna-
tional scientific advisory board 
identified a set of crucial scientific 
problems that must be solved in 
order to make real progress in pre-
venting and treating diseases that 
kill millions of people every year 
in the developing world. These 14 
Grand Challenges include devel-
oping vaccines that do not require 
refrigeration, designing antigens to 
provoke protective immunity, find-
ing ways to control insect vectors of 
disease, inventing therapies to cure 
latent infections, and creating new 
health-assessment tools for regions 
lacking reliable recordkeeping or 
sophisticated laboratories.
Last summer, after a long, rigor-
ous, and highly competitive selec-
tion process, the Grand Challenges 
program awarded $436.6 million to 
43 innovative research projects, to 
be carried out by investigators in 33 
countries. The endeavor “is a great 
opportunity to allow people to think 
a little bit out of the box about some 
problems that are incredibly hard,” 
says Carol Dahl, director of global 
health technologies at the Gates 
Foundation in Seattle. The initiative is 
financed with a total of $450 million 
from the Foundation, $27.1 million 
from the Wellcome Trust, and $4.5 
million from the Canadian Institutes 
of Health Research.The Grand Challenges effort is 
one of the most ambitious projects 
launched by the Gates Founda-
tion to date. Since its inception in 
1998, the charity has pledged more 
than $6 billion to improving global 
health. This new source of funding 
has dramatically pumped life—and 
optimism—into the long-parched 
landscape of research and devel-
opment into diseases that primarily 
afflict the developing world, such as 
AIDS, malaria, and tuberculosis as 
well as neglected tropical illnesses 
such as hookworm, schistosomia-
sis, and Chagas disease.
Sponsoring research as well as dis-
ease prevention and treatment efforts, 
the Foundation has dedicated $1.1 
billion to fighting AIDS/HIV, $640 mil-
lion to combating malaria, and $900 
million to tuberculosis. It has poured 
another $1.5 billion into the Global 
Alliance for Vaccines and Immuniza-
tion (GAVI), a Geneva-based coali-
tion that has delivered traditional and 
new vaccines to roughly 130 million 
youngsters—saving an estimated 1.7 
million lives in more than 70 coun-
tries. Catalyzed by the Gates’ largess, 
other nonprofit organizations and 
government agencies have joined the 
cause. Bill Gates has “made global 
health sexy,” says tropical diseases 
researcher Peter Hotez of George 
Washington University in Washing-
ton, DC, who is working on a vaccine 
to combat hookworm.
Betting on Science
The Grand Challenges program 
epitomizes the Gates Foundation’s 
support of high-risk and large-scale 
research proposals that are unlikely 
to receive traditional kinds of fund-
ing. For example, molecular biologist 
Anthony James at the University of 
California, Irvine and his collabora-Cell 124, Febtors (from eight other universities 
and one biotechnology firm) are 
engineering transgenic mosquitoes 
with a $19.7 million grant, one of 
several funded approaches to Grand 
Challenge #7, which aims to prevent 
insect vectors from transmitting 
infectious diseases.
The mosquito species they are 
studying is Aedes aegypti. This insect 
transmits a potentially fatal tropical 
pathogen called dengue virus that 
infects 50 to 100 million people each 
year worldwide and has caused seri-
ous epidemics in South-East Asia, 
islands of the Western Pacific, and 
South America. James, arbovirologist 
Kenneth Olson of Colorado State Uni-
versity, and their colleagues are engi-
neering Aedes to express a synthetic 
gene construct that results in destruc-
tion of the dengue virus genome. 
Although still far off, the ultimate goal 
is to release the transgenic insects 
into the wild, enabling the gene to 
move through the native mosquito 
population and thus helping to break 
the disease transmission cycle.
The core of the synthetic construct 
encodes a double-stranded RNA—
designed by Olson’s lab—formed by 
the sense and antisense sequences 
of a segment from the RNA genome 
of dengue virus serotype 2. When the 
double-stranded RNA is expressed in 
cells of the mosquito midgut, an innate 
immune response called RNA inter-
ference (RNAi) is activated that chops 
up the RNA genome of dengue virus 
ingested in an infected blood meal. In 
lab studies, the strategy appears to 
work, James says. Transgenic mos-
quitoes challenged with a dengue 
virus-infected blood meal exhibit only 
very low titers of the pathogen.
The major hurdle now is finding 
a way to drive the synthetic gene 
through a wild-type mosquito popula-ruary 24, 2006 ©2006 Elsevier Inc. 661
tion. The consortium is testing several 
methods. James’ group is hitching the 
anti-dengue virus construct to a DNA 
element called a transposon that can 
move through the mosquito genome, 
potentially replicating itself many 
times with each reproductive cycle. To 
express the transposable elements in 
the mosquito germline (so that all gen-
erations of progeny carry the accom-
panying anti-dengue construct), and 
to prevent this genetic weapon from 
spreading into nontarget organisms, 
the scientists have linked a transpo-
son called Mos1 to a species-spe-
cific mosquito promoter of nanos, 
a developmentally regulated insect 
gene. The transposition is activated 
in the mosquito embryo during early 
development, but only at one pole—
where future egg and sperm will form. 
Putting it all together, the researchers 
are now transforming mosquitoes with 
the entire transposon-plus-anti-den-
gue construct and analyzing whether 
the “gene drive” is effective.
Within 5 years, the research con-
sortium hopes to take several varie-
ties of their transgenic, dengue virus-
fighting mosquitoes into greenhouse 
field studies in a tropical country 
where dengue fever is endemic. The 
National Institutes of Health (NIH) 
does not fund such ambitious bench-
to-field projects, James says. Only 
Gates is “willing to take the gamble.” 
For the first time, a lack of resources 
isn’t a barrier, he says.
Tapping Nature’s Defenses
Another Grand Challenges goal is to 
surmount the major difficulty of deliv-
ering viable vaccines to people in the 
developing world where a break in 
the “cold chain” of refrigerators and 
cold boxes may lead to inactivation of 
vaccines. Abraham L. Sonenshein, a 
molecular geneticist at the Tufts Uni-
versity School of Medicine in Boston, 
has come up with one possible solu-
tion. He is using a $5 million award to 
engineer a vaccine that is packaged in 
heat-resistant bacterial spores. Imper-
vious to heat, cold, radiation, antibiot-
ics, and low pH, “bacterial spores are 
just about the most resistant biologi-
cal entities that we know, ” he says.
Sonenshein and his collabora-662 Cell 124, February 24, 2006 ©2006 Etors are splicing vaccine antigens for 
diphtheria, pertussis, and tetanus into 
the genome of Bacillus subtilis so that 
the innocuous soil bacterium displays 
those proteins on its surface in its 
replicative phase or its spore phase, 
or both. The genetically engineered 
spores could be freeze-dried and 
stored in aluminum packets for years 
at any temperature. When needed, 
the spore vaccine could be mixed 
with water and given to people as a 
drink. In theory, following ingestion, 
some spores would adhere to the 
intestinal tract and would germinate, 
releasing bacteria capable of replica-
tion. The primary hurdle, says Sonen-
shein, will be to ensure that enough 
antigen is presented to intestinal cells 
to trigger a sufficiently strong immune 
response that creates protective 
immunity. Sonenshein and his col-
leagues are also working on a spore 
vaccine for rotavirus, a diarrheal infec-
tion that kills roughly 500,000 children 
worldwide each year. They hope to 
take their experimental vaccines into 
human clinical trials within 5 years.
Meanwhile, another Grand Chal-
lenges team is using a $19 million 
grant to characterize the molecu-
lar basis of innate immunity against 
malaria, which kills more than 1 mil-
lion people annually, most of them 
children in Africa. Young children 
who survive multiple infections of 
the malaria parasite Plasmodium 
falciparum seem to acquire natural 
resistance to severe forms of the 
disease. A group led by Army phy-
sician Patrick Duffy, a researcher 
at the Seattle Biomedical Research 
Institute, will screen blood samples 
from 14,000 babies, young children, 
and adults in Tanzania to determine 
whether specific phenotypes of the 
P. falciparum parasite are responsi-
ble for severe childhood malaria.
Using mass spectrometry and 
microarray analysis, the investiga-
tors will search for any unique para-
site proteins that provoke an anti-
body response and then will examine 
whether individuals producing those 
antibodies are less susceptible to 
severe illness or death. “Once you 
know what protective immunity is, it 
provides a very economical pathway lsevier Inc.to determining what are the proteins 
that should be put into a vaccine,” 
says Duffy.
From Lab Research to Field 
Reality
To maximize the odds of achieving 
their research goals, principal inves-
tigators of Grand Challenges projects 
are required to stipulate milestones 
and timelines for their work. For-profit 
grantees are used to such planning 
exercises, but the academics found 
it “a little bit more challenging,” says 
Daniel Carucci, director of the Grand 
Challenges in Global Health at the 
Foundation of the NIH (FNIH). (The 
FNIH, an independent public char-
ity that administers private grants to 
support NIH programs or other com-
plementary research, is managing 21 
Grand Challenges awards.)
The grantees also must be pre-
pared to ensure that any medicines or 
other health tools created with Grand 
Challenges money will be available 
at affordable prices to developing 
nations. The program “is definitely 
not about generating new knowledge 
in and of itself—it’s about solving 
problems,” says Carucci. In a “global 
access strategy,” principal investi-
gators are required to outline intel-
lectual property ownership issues, 
licensing strategies, and potential 
commercial partners. Scientists can 
patent their work, but if they fail to 
make their inventions accessible to 
poor countries, their award contracts 
include fallback provisions, such 
as requiring the grantee to give the 
FNIH a license to fulfill the charitable 
mission, says Carucci.
Some public health experts have 
criticized the Grand Challenges ini-
tiative for investing too heavily in 
speculative high-tech ideas. They 
say the funds could be used to help 
save more lives today by distributing 
existing medicines or helping to build 
clean water and sanitation systems 
or combating malnutrition. But oth-
ers say that current treatments aren’t 
enough, pointing to malaria’s resur-
gence in recent decades because 
resistance to insecticides has devel-
oped in the mosquito vector that 
transmits the malaria parasite. “You 
need to use existing control tools that 
you have at hand, and be able to fold 
in the new ones over time,” says Hotez 
at George Washington University.
Although some Gates grants do 
support health systems and infra-
structure, the charity’s general view 
is that governments bear primary 
responsibility for improvements in 
those areas. But Regina Rabinovich, 
the Gates Foundation’s director of 
infectious diseases, acknowledges 
that the world’s overall funding pie 
needs to grow to cover both basic 
health needs and future interven-
tions. “It doesn’t help to develop new 
drugs, vaccines or diagnostics if you 
can’t use them,” Rabinovich says.
In fact, assessments of the Gates-
funded immunization campaign, 
GAVI, have underscored to global 
health experts the importance of 
investing in the health systems of 
developing countries. The vaccine 
alliance’s experience holds signifi-
cant implications for other global 
health initiatives, including the Grand 
Challenges program. This is due to 
the fact that new vaccines or medi-
cal treatments might eventually be 
distributed to developing countries 
through the GAVI system or through 
similar public-private partnerships.
Getting Vaccines to the Needy
Launched in 2000 with $750 million 
of Gates seed money, GAVI rapidly 
provided 5-year grants to the needi-
est countries to purchase (through 
UNICEF) and deliver new and under-
used childhood vaccines. The inno-
vative public-private partnership 
includes UNICEF, the World Health 
Organization (WHO), vaccine mak-
ers, and governments of many indus-
trialized nations that also contributed 
millions to the mission.
With GAVI funds, countries have 
vaccinated 90 million children against 
hepatitis B; 14 million against Haemo-
philus influenza type b (Hib), a major 
cause of meningitis and pneumonia; 
and 14 million against yellow fever. 
And basic vaccines against diphtheria, pertussis, and tetanus have reached 
13 million extra youngsters. Thanks to 
GAVI and the Gates Foundation, “it’s 
really a huge breakthrough that we are 
working toward a vision of the kids in 
poor countries having access to the 
same vaccines that my kids get,” says 
Ruth Levine, a health financing expert 
at the Center for Global Development 
(CGD) in Washington, DC.
Despite these successes, analy-
ses show the alliance has encoun-
tered some major difficulties on the 
ground. One study (funded by Save 
the Children UK) found that immuni-
zation efforts in developing countries 
were hindered by a shortage of some 
vaccines and by deep-seated weak-
nesses in health care infrastructure. 
These deficiencies included short-
ages of staff workers and transport 
vehicles, unreliable health informa-
tion systems, and breakdowns in the 
vaccine cold chain.
In his book Crusade to Immu-
nize the World’s Children, Wil-
liam Muraskin, a social historian at 
Queens College of the City Univer-
sity of New York, says the coalition 
imposed a vaccine-focused agenda 
on the health ministries of poor 
nations that didn’t pay sufficient 
attention to their most urgent dis-
ease-fighting priorities. And although 
the alliance predicted that by the end 
of 5 years vaccine prices would drop 
and countries would be able to take 
over the costs of the hepatitis B and 
Hib vaccines—which in some cases 
doubled or tripled national immuni-
zation expenses—neither happened, 
says CGD’s Levine. Given the situa-
tion, Muraskin questions how GAVI 
will succeed in its plans to introduce 
even pricier vaccines against rota-
virus and pneumonia, or future vac-
cines against malaria, HIV, and TB.
Jean-Marie Okwo-Bele, WHO’s 
director of immunization, vaccines, 
and biologicals and a former health 
official in the Democratic Republic 
of Congo, says that GAVI “has been 
successful on several fronts, and like 
any other thing, it also has some areas Cell 124, Fethat need improvements.” He agrees 
that the coalition went in with “a bit too 
much of a top-down approach,” but it 
recently set up sound processes for 
receiving more input from the health 
ministries of developing countries. 
“GAVI is certainly taking the lessons 
forward,” Okwo-Bele says.
For instance, GAVI is providing a 
second phase of financing to coun-
tries over a longer, 10 year term, 
with recipients paying a gradually 
increasing share of vaccine costs. 
It is also offering more funding to 
shore up basic health services at 
the district level, says GAVI execu-
tive secretary Julian Lob-Levyt. The 
Gates Foundation has demonstrated 
its continuing support with another 
$750 million award, and even more 
importantly, six nations have agreed 
to set up a financing mechanism that 
will raise $4 billion over a decade. As 
for sustainability, deciding to deny 
the world’s poorest people the ben-
efits of health because their nations 
will never have enough money to pay 
for new medicines is “not accept-
able,” says Lob-Levyt. “We have to 
be much more ambitious.”
Other Gates grantees are watching 
GAVI closely. At the Malaria Vaccine 
Initiative in Seattle, director Melinda 
Moree and associates have begun 
laying the groundwork to avoid 
similar problems when they bring a 
malaria vaccine to market, hopefully 
within the next decade. What wor-
ries Moree most isn’t failure to create 
an effective treatment—it’s inventing 
one that nobody could afford or get 
access to. “That would be the worst 
outcome,” she says.
As the Gates Foundation’s Rab-
inovich puts it, success is not defined 
as licensing a new drug; it is meas-
ured by actual impact on people’s 
health. Ultimately, one of the big-
gest challenges is guaranteeing that 
any medical solutions designed for 
poor countries—whether through the 
Grand Challenges program or any 
other global health initiative—reach 
those who need them most.
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